Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

VX-765 identified as a strong candidate therapy for multiple sclerosis

Staff Writer
Staff Writer 2 years ago
Updated 2020/10/20 at 10:27 PM
Share
SHARE

Researchers at the University of Alberta have identified a strong candidate therapy for multiple sclerosis known as VX-765.

Published in the journal Glia, the anti-inflammatory drug is purported to substantially reduce the disease’s progression, becoming a central focus on the discovery of a newer effective treatment for multiple sclerosis.

“Inflammatory demyelination and axonal injury in the central nervous system (CNS) are cardinal features of progressive multiple sclerosis (MS), and linked to activated brain macrophage‐like cells (BMCs) including resident microglia and trafficking macrophages,” the co-authors detailed in their journal article.

“Caspase‐1 is a pivotal mediator of inflammation and cell death in the CNS. We investigated the effects of caspase‐1 activation and its regulation in models of MS,” they added.

According to researchers, inflammation is believed to be pivotal in the development of multiple sclerosis. Molecules known as inflammasomes are behind the activation of an inflammatory response in the body; the new candidate drug VX-765 experimented on rodents, inhibits caspase-1, thus reducing the likelihood of harmful inflammation.

“The study shows intranasal therapy is effective in preventing demyelination and axon injury and loss, so that’s a real tonic for us to keep going,” the co-authors explained in a news release.

“The loss of myelin and loss of nerves are irreversible processes, so any therapeutic that helps to slow or prevent that from happening is an exciting advance for MS research.”

The study was funded by the Alberta Innovates‐Health Solutions Collaborative Research and Innovation Opportunities Team grant (AIHS‐CRIO).

Photo: Shutterstock

You Might Also Like

Study finds mental distress affects almost half of all teenage females in Norway

ICD-11 lists complex post-traumatic stress disorder as a new condition

New research identifies personality traits linked to cognitive deficits

Many known biological pathways in the brain are impacted by Alzheimer’s disease

Immune system and CNS may play a major role in ALS

TAGGED: multiple sclerosis, myelin, VX-765
Staff Writer October 20, 2020
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Higher-calorie diets could lead to a speedier recovery in patients with anorexia nervosa
Next Article Researchers explore prejudice against Asian Americans during the COVID-19 pandemic

Recommended

Clinical

Study finds mental distress affects almost half of all teenage females in Norway

1 Min Read
Clinical

ICD-11 lists complex post-traumatic stress disorder as a new condition

1 Min Read
Clinical

New research identifies personality traits linked to cognitive deficits

1 Min Read
Clinical

Many known biological pathways in the brain are impacted by Alzheimer’s disease

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?